Publications by authors named "Philip W Kantoff"

100Publications

Inferences about drug safety in phase 3 trials in oncology: Examples from advanced prostate cancer.

J Natl Cancer Inst 2020 Aug 28. Epub 2020 Aug 28.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djaa134DOI Listing
August 2020

Effects of acupuncture versus cognitive behavioral therapy on cognitive function in cancer survivors with insomnia: A secondary analysis of a randomized clinical trial.

Cancer 2020 Jul 22;126(13):3042-3052. Epub 2020 Apr 22.

Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32847DOI Listing
July 2020

and COVID-19: Serendipity or Opportunity for Intervention?

Cancer Discov 2020 06 10;10(6):779-782. Epub 2020 Apr 10.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-20-0451DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437472PMC
June 2020

Methylation-associated miR-193b silencing activates master drivers of aggressive prostate cancer.

Mol Oncol 2019 09 19;13(9):1944-1958. Epub 2019 Jul 19.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/1878-0261.12536DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717747PMC
September 2019

Aneuploidy drives lethal progression in prostate cancer.

Proc Natl Acad Sci U S A 2019 06 13;116(23):11390-11395. Epub 2019 May 13.

David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1902645116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561291PMC
June 2019

Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types.

Clin Cancer Res 2019 Jul 22;25(14):4290-4299. Epub 2019 Apr 22.

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-0404DOI Listing
July 2019

Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications.

Eur J Cancer 2019 05 6;112:118-126. Epub 2019 Mar 6.

HealthCore-NERI, 480 Pleasant Street, Watertown, MA 02472, USA; Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.11.033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501826PMC
May 2019

Time to Prostate-specific Antigen Nadir and the Risk of Death From Prostate Cancer Following Radiation and Androgen Deprivation Therapy.

Urology 2019 04 18;126:145-151. Epub 2019 Jan 18.

Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2018.11.056DOI Listing
April 2019

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry.

Prostate Cancer Prostatic Dis 2019 09 14;22(3):420-427. Epub 2019 Jan 14.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41391-018-0121-2
Publisher Site
http://dx.doi.org/10.1038/s41391-018-0121-2DOI Listing
September 2019

A Prospective Study of Aspirin Use and Prostate Cancer Risk by Status.

Cancer Epidemiol Biomarkers Prev 2018 10 14;27(10):1231-1233. Epub 2018 Aug 14.

National Cancer Institute, Division of Cancer Epidemiology and Genetics, Epidemiology and Biostatistics Program, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-18-0510DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170677PMC
October 2018

Regular aspirin use and gene expression profiles in prostate cancer patients.

Cancer Causes Control 2018 Aug 18;29(8):775-784. Epub 2018 Jun 18.

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10552-018-1049-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298857PMC
August 2018

Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer.

J Endocr Soc 2018 May 20;2(5):485-496. Epub 2018 Apr 20.

Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/js.2018-00039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941157PMC
May 2018

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Eur Urol 2019 01 16;75(1):88-99. Epub 2018 Apr 16.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA; Department of Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.03.028DOI Listing
January 2019

Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer.

Cancer 2018 04 16;124(7):1391-1399. Epub 2018 Jan 16.

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31217
Publisher Site
http://dx.doi.org/10.1002/cncr.31217DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982532PMC
April 2018

Current treatment strategies for advanced prostate cancer.

Int J Urol 2018 03 20;25(3):220-231. Epub 2017 Dec 20.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iju.13512DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053280PMC
March 2018

Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer.

PLoS One 2017 8;12(9):e0184166. Epub 2017 Sep 8.

Division of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0184166PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590894PMC
October 2017

Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?

J Clin Oncol 2017 10 17;35(29):3272-3274. Epub 2017 Aug 17.

Lorelei A. Mucci, Harvard TH Chan School of Public Health, Boston, MA; and Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.7915DOI Listing
October 2017

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.

J Clin Oncol 2017 09 10;35(27):3097-3104. Epub 2017 Aug 10.

Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer Institute, Boston, MA; Marc Buyse, International Drug Development Institute; Bertrand Tombal, Université Catholique de Louvain, Louvain-la-Neuve; Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor, Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation, Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA; Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, University College London, London, United Kingdom; James J. Dignam, University of Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France; Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.9987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652387PMC
September 2017

Cancer nanomedicine: progress, challenges and opportunities.

Nat Rev Cancer 2017 01 11;17(1):20-37. Epub 2016 Nov 11.

Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc.2016.108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575742PMC
January 2017

Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer.

J Clin Oncol 2017 01 30;35(1):124-125. Epub 2016 Sep 30.

Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; James L. Gulley, National Cancer Institute, Bethesda, MD; and Cesar Pico-Navarro, Bavarian Nordic, Redwood City, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.7748DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411419PMC
January 2017

Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial.

J Clin Oncol 2016 11;34(31):3781-3786

Nicholas J. Giacalone, Marian Loffredo, and Anthony V. D'Amico, Brigham and Women's Hospital/Dana-Farber Cancer Institute; Nicholas J. Giacalone, Harvard Radiation Oncology Program, Boston, MA; Jing Wu and Ming-Hui Chen, University of Connecticut, Storrs, CT; Andrew Renshaw, Miami Baptist Hospital, Miami, FL; and Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.4530DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791839PMC
November 2016

Physical and emotional health information needs and preferences of long-term prostate cancer survivors.

Patient Educ Couns 2016 12 14;99(12):2049-2054. Epub 2016 Jul 14.

Perini Family Survivors' Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, 25 Shattuck Street, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pec.2016.07.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675563PMC
December 2016

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

N Engl J Med 2016 Aug 6;375(5):443-53. Epub 2016 Jul 6.

From the University of Washington (C.C.P., M. Beightol, C.M., B.N., H.H.C., B.M., T.W., S. Casadei, P.S.N.) and Fred Hutchinson Cancer Research Center (N.D.S., R.G., P.S.N.) - both in Seattle; the Institute of Cancer Research and Royal Marsden Hospital, London (J.M., S. Carreira, R.E., J.B.); Memorial Sloan Kettering Cancer Center (M.F.W., W.A., M. Berger, L.Z., A.Z., J. Vijai, H.I.S., C.S., N.S., P.W.K., D.S., M.R., K.O.), Weill Cornell Medical College (H.B., O.E., M.A.R.), and the Prostate Cancer Clinical Trials Consortium (J. Vinson, J.F.) - all in New York; the University of Michigan, Ann Arbor (D.R., R.L., M.H., A.C.); Howard Hughes Medical Institute, Chevy Chase, MD (A.C., C.S.); and Dana-Farber Cancer Institute, Boston (A.G., L.G., M.-E.T., S.A., G.C.H., E.M.V.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1603144DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986616PMC
August 2016

Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.

Proc Natl Acad Sci U S A 2016 May 16;113(22):6259-64. Epub 2016 May 16.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215; Harvard Medical School, Boston, MA 02215

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1600420113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896695PMC
May 2016

A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.

J Clin Oncol 2016 06 4;34(16):1913-20. Epub 2016 Apr 4.

Rana R. McKay, Lillian Werner, Christopher J. Sweeney, Philip W. Kantoff, and Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston; Robert W. Ross, Bluebird Bio, Cambridge, MA; Amado J. Zurita and Hai T. Tran, MD Anderson Cancer Center, Houston, TX; Justine Y. Bruce, University of Wisconsin Carbone Cancer Center, Madison, WI; Michael A. Carducci, Johns Hopkins University; Arif Hussain, Greenebaum Cancer Center, Baltimore, MD; Mark N. Stein, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Elisabeth I. Heath, Karmanos Cancer Institute, Detroit, MI; and Philip W. Kantoff and Susan F. Slovin, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.3154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321094PMC
June 2016

Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer.

Nat Commun 2016 Mar 15;7:10982. Epub 2016 Mar 15.

Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms10982DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796315PMC
March 2016

Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer--Reply.

JAMA 2016 Mar;315(10):1055-6

Department of Medicine, Dana Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2015.17570DOI Listing
March 2016

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol 2016 Apr 22;34(12):1402-18. Epub 2016 Feb 22.

Howard I. Scher, Michael J. Morris, Dana E. Rathkopf, and Susan F. Slovin, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; David Nanus, NewYork Presbyterian Weill Cornell Medical Center; Lawrence W. Schwartz, NewYork Presbyterian Columbia University Medical Center, New York, NY; Walter M. Stadler, University of Chicago Medicine, Chicago, IL; Celestina Higano and Peter S. Nelson, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Ethan Basch, University of North Carolina at Chapel Hill, Chapel Hill, NC; Emmanual S. Antonarakis and Michael A. Carducci, Johns Hopkins University School of Medicine, Baltimore, MD; Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Paul G. Corn and Christopher Logothetis, MD Anderson Cancer Center, Houston, TX; Robert Dreicer, University of Virginia School of Medicine, Charlottesville, VA; Daniel J. George, Susan Halabi, and Andrew J. Armstrong, Duke University and Duke Cancer Institute, Durham, NC; Elisabeth I. Heath, Wayne State University Karmanos Cancer Institute, Detroit; and Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Wm. Kevin Kelly, Sidney Kimmel School of Medicine at Thomas Jefferson University, Philadelphia, PA; Glenn Liu and George Wilding, University of Wisconsin Carbone Cancer Center, Madison, WI; Mark N. Stein, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ; Charles S. Ryan and Eric J. Small, University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Oliver Sartor, Tulane School of Medicine, New Orleans, LA; Matthew Raymond Smith, Massachusetts General Hospital Cancer Center and Harvard Medical School; Mary-Ellen Taplin and Philip W. Kantoff, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, Franc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.2702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872347PMC
April 2016

Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis.

Prostate 2016 May 5;76(7):691-9. Epub 2016 Feb 5.

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23160DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510241PMC
May 2016

Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.

Clin Genitourin Cancer 2016 08 24;14(4):352-9. Epub 2015 Dec 24.

Bladder Cancer Center, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.12.029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508512PMC
August 2016

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.

Clin Genitourin Cancer 2016 08 17;14(4):e299-305. Epub 2015 Dec 17.

Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.12.008DOI Listing
August 2016

Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.

Can J Urol 2015 Dec;22(6):8048-55

University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

View Article

Download full-text PDF

Source
December 2015

Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations.

JAMA 2015 Nov;314(19):2077-9

Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2015.7273DOI Listing
November 2015

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

N Engl J Med 2015 Nov 25;373(19):1814-23. Epub 2015 Sep 25.

From the Dana-Farber Cancer Institute, Boston (T.K.C., P.W.K.); Institut Gustave Roussy, Villejuif, France (B.E.); Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, London (T.P.); Icon Cancer Care, South Brisbane, QLD, Australia (P.N.M.); Cleveland Clinic, Cleveland (B.I.R.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (H.H.); Texas Oncology-Charles A. Sammons Cancer Center, Baylor University, Dallas (T.E.H.); University of Ulsan College of Medicine (J.-L.L.) and Seoul National University Hospital (B.K.) - both in Seoul, South Korea; Helsinki University Central Hospital Cancer Center, Helsinki (K.P.); Washington University in St. Louis, St. Louis (B.J.R.); Sunnybrook Odette Cancer Centre, Toronto (G.A.B.), and Tom Baker Cancer Centre, Calgary, AB (D.Y.C.H.) - both in Canada; National Institute of Oncology, Budapest, Hungary (L.G.); Hospital de la Santa Creu i Sant Pau, Barcelona (P.M.); Medical University of Vienna, Vienna (M.S.); Exelixis, South San Francisco, CA (A.B-H., C.H., C.S., G.M.S.); University of Texas M.D. Anderson Cancer Center, Houston (N.M.T.); and the Memorial Sloan Kettering Cancer Center, New York (R.J.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024539PMC
November 2015

Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.

JAMA 2015 Sep 22-29;314(12):1291-3

Department of Medicine, Dana Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2015.8577DOI Listing
October 2015

Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.

Clin Cancer Res 2015 Dec 19;21(24):5578-87. Epub 2015 Aug 19.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0824DOI Listing
December 2015